Bile Acid Recognition by the *Clostridium difficile* Germinant Receptor, CspC, Is Important for Establishing Infection

Michael B. Francis, Charlotte A. Allen, Ritu Shrestha, Joseph A. Sorg*

Department of Biology, Texas A&M University, College Station, Texas, United States of America

**Abstract**

*Clostridium difficile* spores must germinate *in vivo* to become actively growing bacteria in order to produce the toxins that are necessary for disease. *C. difficile* spores germinate *in vitro* in response to certain bile acids and glycine. In other sporulating bacteria, proteins embedded within the inner membrane of the spore sense the presence of germinants and trigger the release of Ca\(^{++}\)-dipicolinic acid (Ca\(^{++}\)-DPA) from the spore core and subsequent hydrolysis of the spore cortex, a specialized peptidoglycan. Based upon homology searches of known germinant receptors from other spore-forming bacteria, *C. difficile* likely uses unique mechanisms to recognize germinants. Here, we identify the germination-specific protease, CspC, as the *C. difficile* bile acid germinant receptor and show that bile acid-mediated germination is important for establishing *C. difficile* disease in the hamster model of infection. These results highlight the importance of bile acids in triggering *in vivo* germination and provide the first description of a *C. difficile* spore germinant receptor. Blocking the interaction of bile acids with the *C. difficile* spore may represent an attractive target for novel therapeutics.

**Citation:** Francis MB, Allen CA, Shrestha R, Sorg JA (2013) Bile Acid Recognition by the *Clostridium difficile* Germinant Receptor, CspC, Is Important for Establishing Infection. PLoS Pathog 9(5): e1003356. doi:10.1371/journal.ppat.1003356

**Editor:** Michael R. Wessels, Boston Children’s Hospital, United States of America

**Received** December 30, 2013; **Accepted** March 27, 2013; **Published** May 9, 2013

**Copyright:** © 2013 Francis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by the American Heart Association National Scientist Development grant to JAS (No. 11SDG7160013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: jsorg@bio.tamu.edu

**Introduction**

*Clostridium difficile* infections (CDI) are steadily increasing in the United States and other countries [1,2]. The use of broad-spectrum antibiotics, often unrelated to CDI, leads to alteration of the colonic microbiota that normally provides resistance to *C. difficile* colonization [3]. In a host, *C. difficile* spores must germinate to form the actively growing, anaerobic bacteria that produce the two toxins that are necessary for disease (TcdA and TcdB) [4,5,6]. These two toxins are secreted by the bacterium where they then enter host epithelial cells by receptor-mediated endocytosis and, upon escape into the cytosol, glucosylate members of the Rho-family of GTPases [7]. The action of these toxins lead to symptoms normally associated with CDI (e.g. diarrhea) and release of *C. difficile* spores into the environment [8].

Metabolically dormant spores are formed by selected bacterial species in response to changes in environmental conditions, including nutrient availability [9]. During spore formation, the proteins required for germination are pre-packaged into the spore, priming the spore to germinate when conditions are appropriate [10]. In many spore-forming species, the interaction of the metabolically dormant spore with specific germination-inducing molecules (germinants) leads to the release of large amounts of Ca\(^{++}\)-dipicolinic acid (DPA) from the dehydrated spore core in exchange for water. Subsequently, hydrolases embedded within the spore cortex, a specialized peptidoglycan, become activated and begin cortex hydrolysis. Once the core is rehydrated and the cortex is degraded, a vegetative cell begins to grow out from the germinated spore. This process is largely conserved among spore-forming bacteria, though the signals that initiate germination can vary. In *Bacillus subtilis*, L-alanine or a mixture of L-asparagine, glucose, fructose and potassium ions triggers germination, while spores of certain strains of *Clostridium perfringens* initiate germination in response to inorganic phosphate and sodium ions [11].

The proteins that respond to these signals, *ger* receptors, share homology among many spore-forming bacteria. However, based on homology searches, *C. difficile* is not among the spore-forming bacteria that have such canonical germinant receptors, suggesting that *C. difficile* responds to unique germinants or uses a novel mechanism for spore germination or both [12].

Approximately 30 years ago, Wilson and others showed that certain bile acids increased the frequency of *C. difficile* colony formation from environmental samples [13,14,15]. Bile acids are small amphipathic, cholesterol-based molecules that aid in the absorption of fats and cholesterol during digestion. Typically, the liver synthesizes two main bile acids, cholic acid (3\(\alpha\),7\(\alpha\),12\(\alpha\)-trihydroxy-5\(\beta\)-cholan acid) and chenodeoxycholic acid (3\(\alpha\),7\(\beta\)-dihydroxy-5\(\beta\)-cholan acid), which are further modified with the addition of either a taurine or glycine amino acid [16]. Building on the work of Wilson and others, we demonstrated that all cholic acid derivatives can stimulate *C. difficile* colony formation from spores with approximately equal efficiency [17]. Further, we showed that exposure to the combination of taurocholic acid and glycine were required to initiate *C. difficile* spore germination [17]. Interestingly, chenodeoxycholic acid was unable to stimulate colony formation or the initiation of spore germination [17].
Author Summary

Clostridium difficile infections (CDI) are steadily increasing in the United States and other countries. C. difficile spores are the infectious agent and often contaminate environmental surfaces. However, to initiate infection, C. difficile spores must germinate in vivo to actively growing bacteria. Certain bile acids and glycine are the most effective compounds that stimulate C. difficile spore germination. While the signals that stimulate germination by C. difficile spores are known, with what these compounds interact remains unknown. Here, we identified the germination-specific protease, CspC, as the bile acid germinant receptor. In C. difficile, CspC is not predicted to have catalytic activity. However, we find that mutations in cspC alter the specificity of germinant recognition or abrogate the ability of C. difficile spore to germinate in response to bile acids. Further, we show that bile acid recognition by C. difficile spores is important for establishing infection in an animal model of C. difficile disease. Our results suggest a unique mechanism for C. difficile spore germination through direct stimulation of cortex hydrolysis by a spore germinant. A detailed understanding of germinant recognition by C. difficile CspC may aid in the identification of germination-blocking compounds, which may have importance in hindering C. difficile colonization.

Subsequent studies identified chenodeoxycholic acid as a competitive inhibitor of cholic acid-mediated germination [18,19]. While the chemical signals that promote the initiation of C. difficile spore germination are known, the proteins that respond to these germinants had not been identified.

Here, we applied a screen, previously used to identify loci involved in B. subtilis spore germination [20], to the identification of C. difficile germination-null phenotypes. Using a combination of traditional chemical mutagenesis and contemporary massively parallel DNA sequencing, we identified single nucleotide polymorphisms (SNPs) that give rise to ger phenotypes and characterized the resulting strains. We found that mutations in the C. difficile cspC gene can abrogate the initiation of C. difficile spore germination. Further, we identified a mutation in cspC that allows chenodeoxycholic acid to act as a spore germinant, instead of an inhibitor of germination. These results suggest that C. difficile CspC is the bile-acid-sensing germinant receptor. The identification of the molecular target of bile acids on the C. difficile spore allows us to test, for the first time, the in vivo role of bile acid-mediated germination during C. difficile infection.

Results

Identifying germination-null phenotypes

Previously, we demonstrated that the cholic acid family of bile acids causes spores to initiate germination in rich medium [17]. To identify the C. difficile bile acid germinant receptor, we employed a strategy schematized in Figure 1A. We mutagenized C. difficile strain UK1 [19] using the DNA alkylating agent ethyl methane-sulfonate (EMS). The EMS-mutagenized bacteria were allowed to recover during overnight incubation in fresh medium and spread on solid medium to allow efficient spore formation. Spores were purified and incubated overnight at 37°C in rich medium+10% w/v taurocholic acid ([TA]; 185 mM) to germinate those spores that were still able to respond to TA as a germinant. The spore suspension (containing both germinated and non-germinated spores) was incubated at 65°C for 30 minutes to heat-kill the germinated spores; dormant, non-germinated spores are resistant to 65°C. The surviving spores were artificially germinated using thioglycollate and lysozyme [21] and then plated on rich medium to recover, as colonies, the artificially germinated spores. Mutants that failed to germinate under these conditions were enriched and 10 colonies, among thousands, were isolated and tested for the ability of their spores to germinate in response to TA.

Spores from all 10 isolates (ger1–ger10) were unable to form colonies on rich medium+TA, but did form colonies after artificial germination [21] (Figure 1B; only wild-type C. difficile UK1 and ger1 are shown). This suggests that the ger mutations are either blocked at the outgrowth stage of germination (inability to grow as a vegetative cell from the germinated spore) or blocked in the initiation of germination (inability to respond to TA as a germinant).

Characterizing germination-null C. difficile strains

To determine at what stage the mutants are blocked, we analyzed the initiation of germination as measured by a decrease in A600 over time. Wild-type C. difficile UK1 initiated germination in the presence of 5 mM TA and 50 mM TA but not in the absence of TA (Figure 2A). However, spores derived from C. difficile ger1 (Figure 2B) did not initiate germination even at the highest TA concentration used (50 mM). Also, while wild-type C. difficile released DPA in response to TA and glycine, C. difficile ger1–ger10 spores were unable to release the majority of the stored DPA (Figure 2C); Ca**-DPA release from the spore core is one of the first measurable events in bacterial spore germination [10]. Together, these results suggest that the C. difficile ger isolates are defective in the earliest stages of spore germination and may be defective in recognizing TA as a germinant.

Determining the locations of SNPs that give rise to ger phenotype

The locations of the SNP(s) that gave rise to the germination-null phenotypes were determined using Illumina sequencing technology (Table S1). The DNA sequence of the 10 ger isolates was compared to determine if all had mutations in the same locus or loci. All isolates had in common mutations in 7 loci, with 6 loci having conserved mutations among all isolates (Table 1). Interestingly, C. difficile ger1–ger10 had several different mutations in the cspBAC locus (Table 2). In Clostridium perfringens, CspA, CspB and CspC are germination-specific proteases that cleave the spore cortex lytic enzyme, SICe, to the active form [22,23,24]. This allows precise control of the timing of cortex hydrolysis during germination. C. perfringens CspA, CspB and CspC, all members of the subtilisin-family of proteases, have identifiable catalytic triads, while, in C. difficile, only CspB has obvious catalytic residues. In wild-type C. difficile, cspB and cspA coding sequences have been fused. Further, the CspA and CspC catalytic triads appear to have been lost (Figure S1). Eight of the 10 mutant strains had mutations in cspC (Table 2), suggesting that, despite the apparent absence of catalytic activity, wild-type CspC may still have a role in C. difficile spore germination.

Defining the role of C. difficile cspC during spore germination

To investigate the role of CspC in C. difficile spore germination, we generated a site-directed mutation using TargetRon technology [4,25,26,27,28]. The resulting strain, C. difficile JSC10 (cspC::ermB), is unable to initiate germination in response to TA (Figure 3B) unless provided with the cspBAC locus expressed in trans from a plasmid (Figure 3C); wild-type C. difficile UK1 initiates germination in response to TA (Figure 3A). Interestingly, when C.
C. difficile JSC10 was complemented with the cspBAC locus, spores generated from this strain appear to germinate more rapidly than do C. difficile UK1 spores. Further work will be needed to characterize the germination rates of these spores. When analyzed for DPA release, wild-type C. difficile UK1 and C. difficile JSC10 (pJS123) released DPA while C. difficile JSC10 was unable to release DPA (Figure 3D).

**Mutations in cspC can alter germinant specificity**

It was previously reported that a mutation in sleC prevents C. difficile spore germination [27]. Thus, mutations that affect germination do not necessarily indicate that the gene in which the mutation lies normally codes for a germinant receptor. To test the hypothesis that C. difficile CspC is a bona fide germinant receptor, we again mutagenized C. difficile UK1 and allowed the mutagenized bacteria to form spores. The purified spores were plated on BHIS medium supplemented with 0.5 mM chenodeoxycholic acid. We looked for colony formation after 48 hours of incubation at 37°C. Chenodeoxycholic acid is a competitive inhibitor of cholic acid-mediated germination for C. difficile UK1 [18,19] and other C. difficile strains [29]. Thus, in order to form colonies, these spores must have acquired an altered germinant specificity. Colonies were isolated and the phenotype confirmed as described above. We sequenced cspC from these newly generated strains and identified a single mutation, G457R. When the cspC<sup>G457R</sup> allele was used to complement C. difficile JSC10, we observed that this strain germinated in response to either TA or chenodeoxycholic acid (Figure 4). These results suggest that C. difficile CspC is a receptor for bile acid germinants.

**Bile acid-mediated germination is important for C. difficile infection in hamsters**

The in vivo signals that trigger C. difficile spore germination are unknown, though bile acids are obvious candidates [30]. To test whether bile acid-mediated germination is required for C. difficile infection, Syrian hamsters were treated with clindamycin to induce sensitivity to C. difficile colonization and infection; the Syrian hamster has been used for approximately 30 years to assess C. difficile virulence and recapitulates the most severe form of human C. difficile infection, pseudomembranous colitis [31]. Hamsters were gavaged with 1,000 C. difficile UK1 spores or C. difficile JSC10 spores or C. difficile JSC10 (pJS123) spores and monitored for signs of CDI. Animals infected with either C. difficile UK1 or C. difficile JSC10 (pJS123) rapidly succumbed to disease. However, C. difficile JSC10 was unable to cause fulminant CDI and exhibited reduced virulence (Chi-squared: p-value<0.02) (Figure 5). These results show that bile acid-mediated germination is important for C. difficile disease and suggest that inhibiting C. difficile spore germination may have therapeutic potential.

**Discussion**

Classically, germinant receptors are embedded within the inner membrane of bacterial spores [10,32]. Germinants must pass through layers of coat proteins, an outer membrane, the cortex and germ cell wall before interacting with their respective receptors. Upon interaction, Ca<sup>++</sup>-DPA is released from the spore core in exchange for water. This exchange is essential to rehydrate the core and allow metabolism to begin. In some bacteria, the release of Ca<sup>++</sup>-DPA triggers the activation of cortex hydrolases allowing a vegetative bacterium to grow from the germinating spore [33]. In C. perfringens the germinat-specific proteases cleave the cortex hydrolase, SleC, to an active form [23,24]. The signals that stimulate this proteolysis in C. perfringens are not known. In C. perfringens, CspA, CspB and CspC are all members of the subtilisin family of serine proteases and have complete catalytic triads, suggesting that any one of these proteins can activate SleC-mediated cortex hydrolysis. In C. difficile, the cspB and cspA coding sequences have been fused [34]. Only CspB contains a complete catalytic triad while CspA and CspC have lost their catalytic residues. Based on sequence analysis, one would predict that only CspB would have an active role in stimulating C. difficile cortex
Indeed, a recent study by Adams and colleagues has shown that CspBA undergoes autoprocessing to generate CspB, which can cleave the cortex hydrolase pro-SleC to an active form [34]. We have provided evidence that C. difficile CspC plays an active and essential role during germination by functioning as the bile acid germinant receptor.

In C. difficile CspC, two of the three catalytic residues have been lost, T170 (conserved H198 in C. perfringens CspC) and G485 (conserved S517 in C. perfringens CspC) (Figure S1 – red). Interestingly, several of the SNPs identified in the germination-null screen lie near T170 or G485 (Figure S1 – green). When we screened for C. difficile mutants that germinated in response to an inhibitor of germination (chenodeoxycholic acid), we identified G457R (Figure S1 – yellow). This residue is approximately 30 amino acids removed from G485. G457R, being a fairly drastic substitution, may modify the bile acid binding pocket to allow for a less-stringent recognition of germination-inducing bile acids. The 12β-hydroxyl group that differentiates between cholic acid and chenodeoxycholic acid protrudes from the molecule. This hydroxyl, in wild-type CspC, may penetrate the hypothetical binding pocket, resulting in a conformational change that is transmitted to C. difficile CspB [34]. CspB would then cleave SleC, initiating cortex hydrolysis [34]. Two of the identified SNPs in the germination-null screen were nonsense mutations in cspBA (Q632stop and W359stop). In the CspBA hybrid protein, Q632 is located in CspA while W359 is in CspB. The generation of a premature stop codon in cspB would result in a truncated protein with an incomplete catalytic triad [34]. The precise role of CspA in C. difficile spore germination is unknown, though our data suggest that CspA may be important.

Our data indicate that host-derived bile acids mediate C. difficile spore germination and that recognition of bile acids is required for infection in the hamster model to be maximally effective. Still, 50% of the animals succumbed to disease when infected with the cspC mutant, suggesting (i) that enough spores spontaneously germinated in the GI tract of the animal to cause disease, or (ii) that other, as yet unidentified, host signals can stimulate spore germination. Lysozyme is able to induce germination of C. difficile spores in vitro [21]. However, recent evidence has suggested that lysozyme at physiological levels may not be able to stimulate C. difficile spore germination [35] and we observe most efficient lysozyme-mediated spore germination after spore coat removal. Further study will be needed to determine if other signals provided by the host can stimulate C. difficile spore germination.

Previously, we identified inhibitors of C. difficile spore germination that had increased potency when compared to chenodeoxycholic acid [19]. It is not yet known whether these germination inhibitors have therapeutic importance but a recent study by

Figure 2. C. difficile ger isolates fail to initiate germination. Purified C. difficile UK1 spores (A) or C. difficile ger1 spores (B) were suspended in BHIS medium (●) or BHIS medium supplemented with 5 mM TA (■) or 50 mM TA (▲) and the initiation of germination was followed at A600. (C) DPA release from spores suspended in germination buffer supplemented with TA and glycine was analyzed at A270.

doi:10.1371/journal.ppat.1003356.g002
Howerton and coworkers have shown dosing antibiotic-treated mice with an inhibitor of germination can reduce disease severity [36]. The identification of the molecular target of bile acids in the C. difficile spore may allow even more potent inhibitors to be rationally designed. Further, these inhibitors may aid in the identification in the bile acid-binding pocket in CspC by providing high-affinity interaction, instead of the relatively low affinity (in the mM range) for taurocholic acid [19,37].

The relative affinities of bile acids for the C. difficile spore were determined using kinetics of germination [18,19,37,38,39]. While these studies were important milestones in determining which bile acids affect C. difficile germination and what features are important for triggering or inhibiting germination, the precise interaction of the bile acid with the germinant receptor has not been analyzed. Also, it has been proposed that the bile acid germinant receptor binds taurocholic acid cooperatively [37]. The identification of the bile acid germinant receptor now permits testing these interactions.

Stimulation of cortex hydrolysis may not be sufficient to fully activate C. difficile spore germination. C. difficile spores suspended in buffered taurocholic acid alone do not initiate spore germination unless a co-germinant, glycine, is added [17]. This suggests that a second, glycine-sensing receptor is required to trigger germination and the return to vegetative growth. We hypothesize that this other receptor may be localized to the inner membrane to aid in the release of Ca$^{2+}$-DPA from the spore core during germination.

### Materials and Methods

#### Ethics statement

All animal procedures were performed with prior approval from the Texas A&M Institutional Animal Care and Use Committee. Animals showing signs of disease were euthanized by CO$_2$ asphyxia followed by thoracotomy as a secondary means of death, in accordance with Panel on Euthanasia of the American Veterinary Medical Association. Texas A&M University’s approval of Animal Use Protocols is based upon the United States Government’s Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research and Training and complies with all applicable portions of the Animal Welfare Act, the Public Health Service Policy for the Humane Care and Use of Laboratory Animals, and all other federal, state, and local laws which impact the care and use of animals.

### Bacterial strains and growth conditions

C. difficile UK1 [19] (Table 3) was grown in a Model B, Coy Laboratory Chamber at 37°C under anaerobic conditions (85% nitrogen, 10% hydrogen, 5% carbon dioxide) in BHIS medium (Brain Heart Infusion supplemented with 5 g/L yeast extract and 0.1% L-cysteine). Antibiotics were added as needed (20 μg/ml thiamphenicol, 10 μg/ml lincomycin, 5 μg/ml rifampin). E. coli DH5α [40] was routinely grown at 37°C in LB medium. Antibiotics were added as needed (50 μg/ml kanamycin or 20 μg/ml chloramphenicol). Bacillus subtilis was grown at 37°C in LB medium and antibiotics were added as needed (2.5 μg/ml chloramphenicol, 5 μg/ml tetracycline).

### EMS mutagenesis

One overnight culture of C. difficile UK1 was diluted 1:100 in 5 ml fresh medium and grown to OD$_{600}$ = 0.5 before adding ethyl methanesulfonate (EMS) to 1% final concentration. The culture was incubated for 3 hours, washed in BHIS medium and recovered overnight in 40-ml BHIS. A sample was taken to score mutation frequency on rifampin-containing BHIS agar medium (Table S2) and 50-μL samples were spread on 20 BHIS plates to allow spore formation of the mutagenized bacteria. Plates were incubated for 4 days before spores were harvested and purified as described previously [19]. Purified spores were suspended in 40 ml BHIS+10% w/v taurocholic acid (TA) and incubated overnight at 37°C to germinate those spores that recognized TA as a germinant. Spores were collected and heated to 65°C for 1 hour to inactivate germinated spores (dormant spores are resistant to 65°C). To germinate the remaining dormant spores, spores were again collected and treated with 250 mM thiglycollate for 30 min at 50°C followed by incubation with 4 mg/ml lysozyme for 15 min at 37°C [21] and 25-μL aliquots were spread on BHIS agar plates to allow spore formation. To enrich for germination null phenotypes, spores were again collected and germinated as described above.

To select for mutations that change the affinity of the germinant receptor from TA to chenodeoxycholic acid, C. difficile UK1 was mutated as described above with the following modification. Purified spores generated from mutated bacteria were spread on BHIS medium supplemented with 0.5 mM chenodeoxycholic acid. Colonies from spores that germinated on this medium were purified and the germination phenotype of their spores was confirmed using standard germination techniques (below).

### Table 1. Locations of the SNPs common to all 10 C. difficile ger isolates. Gene numbering is based upon C. difficile R20291 gene numbering.

| Location | Mutation | Putative Function |
|----------|----------|-------------------|
| Nt 129662 | C→T | N/A |
| CD901 | No aa change | Pseudogene |
| CD1322 | Q138K | Putative ruberythrin |
| CD1848 | S308A | Putative peptidase |
| CD1913 | K82fs | AraC-family transcriptional activator |
| CD2020 | P211L | Putative histidine protein kinase |
| CspBAC | Various (see Table 2) | Germination-specific protease |

| Strain | Mutation(s) |
|--------|-------------|
| ger1   | CspC G171R  |
| ger2   | CspC G171R  |
| ger3   | CspC G483R  |
| ger4   | CspC V272G/S443N |
| ger5   | CspB A632stp |
| ger6   | CspC 5488N  |
| ger7   | CspB A639stp |
| ger8   | CspC G171R  |
| ger9   | CspC G483R  |
| ger10  | CspC G278R  |

Nt: nucleotide.
aa: amino acid.
fs: frame shift.
doi:10.1371/journal.ppat.1003356.t001
doi:10.1371/journal.ppat.1003356.t002
Illumina sequencing

High-quality, high-molecular weight genomic DNA was extracted, as described previously [41,42], and submitted to Tufts University School of Medicine Genomics Core facility for Paired-End 50 Illumina re-sequencing. The samples were sonicated in a 4°C water bath with a Branson sonicator. Illumina libraries were then prepared using the Illumina TruSeq genomic DNA kit and tagged with individual Illumina barcodes. Final libraries were checked on said advanced analytical device, and then diluted to 10 nM prior to being loaded on a lane of an Illumina HiSeq2000. Illumina single-end sequencing was carried out for 50 cycles. The resulting sequence data in fastq format was aligned against the C. difficile genome using CLC Genomics Workbench, and SNPs were called at any position where more than 66% of the reads had an alternate base from the reference

Molecular biology

The Tn916 oriT from Bacillus subtilis Bs49 was amplified using oligonucleotides 5’Tn916SLIC and 3’Tn916SLIC (Table 4) and introduced into the BstAPI restriction site of pBL100 [43] using Sequence and Ligation Independent Cloning (SLIC), generating pJS107. The pJS107 plasmid was used as a TargetTron vector to introduce mutations in to C. difficile. The group II intron insertion sites for C. difficile cspC were identified using an algorithm that can be found at http://dna.med.monash.edu.au/~torsten/intron_site_finder/. The intron fragment was generated as described previously using oligonucleotides cspC (115) EBS2, cspC (115) IBS, cspC (115) EBS1 and EBSU, cloned into pCR2.1-TOPO and then sub-cloned at the HindIII and BsrGI sites of pJS107, yielding pJS130. The B. subtilis – C. difficile shuttle vector, pJS116, was generated through the introduction of the Tn916 oriT into the ApaI restriction site of the E. coli – C. difficile shuttle vector, pMTL84151 [44], using oligonucleotides 5’Tn916ApaI and 3’Tn916ApaI which amplify the Tn916 oriT. The C. difficile cspBAC loci were amplified with Phusion polymerase using 5’cspBA_CXbaI and 3’cspBA_CXhoI oligonucleotides and cloned into the B. subtilis – C. difficile shuttle vector, pJS116. The nucleotide sequences for all constructs were confirmed before use.

Conjugation and mutant selection

B. subtilis BS49 was used as a donor for conjugation with C. difficile. Plasmids were introduced into B. subtilis BS49 using

Figure 3. C. difficile cspC is essential for bile acid-mediated spore germination. Purified C. difficile UK1 spores (A) or C. difficile JSC10 (cspC::ermB) spores (B) or C. difficile JSC10 (cspC::ermB) pJS123 (pcspBAC) (C) were suspended in BHIS medium (●) or BHIS medium supplemented with 5 mM TA (■) or 50 mM TA (▲) and the initiation of germination was followed at A600 (D) DPA release from spores suspended in germination buffer supplemented with TA and glycine was analyzed at A270.

doi:10.1371/journal.ppat.1003356.g003
standard techniques. Conjugation experiments were carried out as described previously [28]. *C. difficile* transconjugants were screened for the presence of Tn916 using tetracycline resistance. Thiamphenicol-resistant, tetracycline-sensitive (plasmid-containing, transposon negative) transconjugants were selected for further use. Potential TargeTron mutants were generated by screening *lincomycin*-resistant *C. difficile* for the insertion of the intron into *C. difficile cspC* using primers specific for full-length *C. difficile cspC*, the 5′ intron insertion site and the 3′ intron insertion site and a positive clone was identified, *C. difficile* JSC10.

Spore germination and DPA release

Spores were purified from BHIS agar medium as described previously [19] with the following modification. Spores from antibiotic-resistant strains (i.e. plasmid-containing or mutant strains) were generated on SMC medium [45] supplemented with appropriate antibiotics and purified as described previously. The initiation of spore germination was analyzed in a Lambda 25 Perkin Elmer spectrophotometer at λ600 every 18 seconds, as

**Figure 5. Bile acid-mediated germination is required for virulence.** Kaplan-Meier survival curve of clindamycin-treated Syrian hamsters inoculated with 1,000 spores of *C. difficile* UK1 or *C. difficile* JSC10 (cspC::ermB) or *C. difficile* JSC10 (cspC::ermB) pJS123 (pCpBAC).

*Figures 4 and 5*.
desc missing in paper
References

1. McDonald LC, Killgore GE, Thompson A, Owens RC, Jr., Kazakova SV, et al. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433–2441.

2. Redelings MD, Soellov, Mascola L (2007) Increase in Clostridium difficile-related mortality rates, United States, 1999–2004. Emerging Infectious Diseases 13: 1417–1419.

3. Wilson KH, Perini F (1988) Role of competition for nutrients in suppression of Clostridium difficile by the clostridial microflora. Infect Immun 56: 2610–2614.

4. Kuhne SA, Carmean ST, Hepp JT, Kelly ML, Cockayne A, et al. (2010) The role of toxin A and toxin B in Clostridium difficile infection. Nature 467: 711–713.

5. Sorg JA, Sonenshein AL (2009) Chenodeoxycholate is an inhibitor of Clostridium difficile. J Bacteriol 191: 5377–5386.

6. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

7. Pruitt RN, Lacy DB (2012) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 46: 373–404.

8. Redelings MD, Sorvillo F, Mascola L (2007) Increase in Clostridium difficile intestinal bacteria. J Lipid Res 47: 241–259.

9. Sorg JA, Sonenshein AL (2010) Inhibiting the initiation of Clostridium difficile spore germination. J Bacteriol 192: 4983–4990.

10. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

11. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 46: 373–404.

12. Wilson KH, Perini F (1988) Role of competition for nutrients in suppression of Clostridium difficile by the clostridial microflora. Infect Immun 56: 2610–2614.

13. Wilson KH (1983) Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 18: 1017–1019.

14. Wilson KH, Kennedy MJ, Fekety FR (1982) Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol 15: 443–446.

15. Sorg JA, Sonenshein AL (2010) Inhibiting the initiation of Clostridium difficile spore germination. J Bacteriol 191: 5377–5386.

16. Ridlon JM, Kang D, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Med Microbiol 55: 217–221.

17. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

18. Sorg JA, Sonenshein AL (2009) Chenodeoxycholate is an inhibitor of Clostridium difficile. J Bacteriol 191: 5377–5386.

19. Sorg JA, Sonenshein AL (2010) Inhibiting the initiation of Clostridium difficile spore germination. J Bacteriol 192: 4983–4990.

20. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

21. Kamiya S, Yamakawa K, Ogura H, Nakamura S (1989) Recovery of spores of Clostridium difficile altered by heat or alkali. J Med Microbiol 28: 217–221.

22. Masayama A, Hamasaki K, Urakami K, Shimamoto S, Kato S, et al. (2006) Expression of germination-related enzymes, CspA, CspB, CspC, SleC, and SleM of Clostridium perfringens spore germinants and sporulation cells. Genes Genet Syst 81: 227–234.

23. Sorg JA, Sonenshein AL (2010) Inhibiting the initiation of Clostridium difficile spore germination. J Bacteriol 192: 4983–4990.

24. Shimamoto S, Moriyama R, Sugimoto K, Miyata S, Makino S (2001) Partial genomic characterization of highly infectious Clostridium difficile 630 spores. J Microbiol 39: 231–238.

25. Sorg JA, Sonenshein AL (2003) Spore germination. Curr Opin Microbiol 6: 550–556.

26. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

27. Burns DA, Hepp JT, Minton NP (2007) NaCl is essential for germination of Clostridium difficile spores in nutrient-rich medium supplemented with the bile salt taurocholate. J Bacteriol 192: 657–664.

28. Carter GP, Douce GR, Govind R, Howarth PM, Mackin KE, et al. (2011) The anti-sigma factor TeoC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog 7: e1002317.

29. Heeg D, Burns DA, Carmean ST, Minton NP (2012) Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One 7: e30316.

30. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

31. Chang TW, Bartlett JG, Goldhor SL, Onderdonk AB (1976) Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun 20: 526–529.

32. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

33. Paidhungat M, Ragkousi K, Setlow P (2001) Genetic requirements for induction of spores of Bacillus subtilis. J Bacteriol 183: 4317–4322.

34. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

35. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

36. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

37. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

38. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

39. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

40. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

41. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Rev Genet 40: 291–324.

42. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

43. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

44. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

45. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

46. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

47. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

48. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

49. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

50. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

51. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

52. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.

53. Poole KS, Lacy DB (2007) Toward a structural understanding of Bacillus subtilis. Annu Review Genet 30: 297–341.